906 followers
New article: Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50 https://t.co/m5gjrAJ6zO #lungcancer #oncology https://t.co/L2AZIOcmYK